Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

Learn more about:
Related Clinical Trial
Retrospective Register for Uveal Melanoma Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma Adjuvant Melatonin for Uveal Melanoma Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma Managed Access Program Supporting Patient Access to Tebentafusp Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Early Integration of Supportive Care Into Standard Oncology Care for Metastatic Uveal Melanoma Patients Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma A Prospective Natural History Study in Uveal Melanoma Uveal Melanoma and Brachytheraphy: Long-term Outcomes. A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation and Randomized, Masked Dose Expansion Designed to Evaluate Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery A Study of PLX2853 in Advanced Malignancies. Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) Treatment Of Radiation Retinopathy Trial Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Study in Subjects With Small Primary Choroidal Melanoma Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Trial of AEB071 in Combination With BYL719 in Patients With Melanoma Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Pembrolizumab in Treating Patients With Advanced Uveal Melanoma Vascular Response to Brachytherapy Using Functional OCT Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma New Biopsy Technique for Uveal Melanoma Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy Intermittent Selumetinib for Uveal Melanoma Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma Vorinostat in Patients With Class 2 High Risk Uveal Melanoma Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases A Phase II Study of BVD-523 in Metastatic Uveal Melanoma Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma Treatment With Intravitreal Avastin for Large Uveal Melanomas

Brief Title

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

Official Title

A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma

Brief Summary

      This phase II trial studies how well vorinostat works in treating patients with melanoma of
      the eye that has spread to other parts of the body (metastatic). Vorinostat may stop the
      growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed Description


      I. To determine the overall objective response rate (RR) to vorinostat in patients with
      metastatic uveal melanoma.


      I. Overall survival (OS). II. Progression free survival (PFS). III. To determine the
      tolerability of vorinostat in patients with metastatic uveal melanoma.


      I. To correlate clinical outcome with changes in histone acetylation status by

      II. To correlate clinical outcome with changes in known proliferation and apoptotic markers
      including Ki67 by immunohistochemistry and BIM, survivin, c-myc, Mcl-1, cleaved PARP,
      gamma-H2AX and RAD51 by western blot.

      III. To assess for changes in pathways such as the MAPK pathway with treatment. IV. To
      describe the evolution of circulating cell-free, tumor-derived deoxyribonucleic acid (DNA)
      levels measured by pyrophosphorolysis activated polymerization (PAP) in plasma of patients
      under treatment for metastatic uveal melanoma.

      V. To correlate overall objective RR with GNAQ, GNA11, SF3B1 and BAP1 mutational status.


      Patients receive vorinostat orally (PO) twice daily (BID) for 3 days weekly for 4 weeks.
      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 12 weeks.

Study Phase

Phase 2

Study Type


Primary Outcome

Overall response rate in patients with uveal melanoma

Secondary Outcome

 Overall survival


Metastatic Uveal Melanoma


Laboratory Biomarker Analysis

Study Arms / Comparison Groups

 Treatment (vorinostat)
Description:  Patients receive vorinostat PO BID for 3 days weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

April 20, 2012

Completion Date

December 31, 2023

Primary Completion Date

December 31, 2023

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have metastatic histologically or cytologically confirmed uveal
             melanoma. (If histologic or cytologic confirmation of the primary is not available,
             confirmation of the primary diagnosis of uveal melanoma by the treating investigator
             can be clinically obtained, as per standard practice for uveal melanoma). Pathologic
             confirmation of diagnosis will be performed at Columbia University, Memorial
             Sloan-Kettering Cancer Center (MSKCC) or Vanderbilt University Medical Center

          -  Patients must have measurable disease as defined by Response Evaluation Criteria in
             Solid Tumors (RECIST) version 1.1

          -  Age >= 18 years. Because limited dosing or adverse event data are currently available
             on the use of vorinostat in patients < 18 years of age, children are excluded from
             this study, but will be eligible for future pediatric single-agent trials, if

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

          -  Life expectancy of greater than 3 months

          -  Leukocytes >= 3,000/mcL

          -  Absolute neutrophil count >= 1,500/mcL

          -  Platelets >= 100,000/mcL

          -  Hemoglobin >= 9.0 g/dL not requiring transfusions within the past 2 weeks

          -  Total bilirubin =< 1.5 x institutional upper limit of normal (ULN); =< 3 x
             institutional ULN if the patient has Gilbert's syndrome

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 2.5 x institutional ULN if no liver metastasis present; =< 5 x institutional ULN if
             liver metastases are present

          -  Creatinine =< 1.5 mg/dL

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Vorinostat is toxic to the developing human fetus. For this reason and because Class D
             agents are known to be teratogenic, women of child-bearing potential and men must
             agree to use effective contraception (hormonal or barrier method of birth control;
             abstinence) prior to study entry and for the duration of study participation. Should a
             woman become pregnant or suspect she is pregnant while she or her partner is
             participating in this study, she should inform her treating physician immediately. Men
             treated or enrolled on this protocol must also agree to use adequate contraception
             prior to the study, for the duration of study participation, and 4 months after
             completion of vorinostat administration

        Exclusion Criteria:

          -  Patients may have had any number of prior therapies. At least 3 weeks must have
             elapsed since the last dose of systemic therapy. At least 6 weeks must have elapsed if
             the last regimen included BCNU or mitomycin C. At least 6 weeks must have elapsed if
             the last regimen included an anti-CTLA4 antibody. Patients must have experienced
             disease progression on their prior therapy in the opinion of the treating investigator

          -  Patients who are receiving any other investigational agents

          -  Patients with active or untreated brain metastases. Treated brain metastases must have
             been stable for at least 2 months

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to vorinostat

          -  Patients receiving HDAC inhibitors or compounds with HDAC inhibitor like activity,
             such as valproic acid, are ineligible. Patients who have received such agents may
             enroll on this study after a 14-day washout period

          -  Patients on warfarin will be excluded from the trial if they cannot be switched to an
             acceptable alternative medication (i.e. low molecular weight heparin [LMWH]).
             Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were
             observed in patients receiving vorinostat concomitantly with coumarin-derivative

          -  Pregnant women are excluded from this study because vorinostat is a Class D agent with
             the potential for teratogenic or abortifacient effects. Because there is an unknown
             but potential risk for adverse events in nursing infants secondary to treatment of the
             mother with vorinostat, breastfeeding should be discontinued if the mother is treated
             with vorinostat

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy will be eligible unless the CD4 count is < 200 cells/mm^3 within one month of
             study enrollment (as requested by Cancer Therapy Evaluation Program [CTEP]). These
             patients are at increased risk of lethal infections when treated with
             marrow-suppressive therapy

          -  A second malignancy requiring active therapy

          -  No concomitant anti-cancer chemotherapy or other systemic drugs. Palliative radiation
             therapy will be allowed as long as the patient meets all other eligibility criteria

          -  Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory
             bowel disease), or significant bowel resection that would preclude adequate absorption

          -  Corrected QT interval (QTc) > 475 milliseconds

          -  Patients who cannot swallow capsules




18 Years - N/A

Accepts Healthy Volunteers



Alexander N Shoushtari, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

National Cancer Institute (NCI)


 Institut Curie Paris

Study Sponsor

Alexander N Shoushtari, Principal Investigator, Memorial Sloan Kettering Cancer Center

Verification Date

February 2023